How Do SNPs Act as Markers in GWAS?
Single nucleotide polymorphisms, commonly referred to as SNPs, serve as foundational genomic landmarks in genome-wide association studies. By identifying variations at specific single-base positions across diverse individuals, researchers can statistically link these genetic variants to particular phenotypes or diseases. This article explores the biological nature of SNPs, their function as proxy markers via linkage disequilibrium, and their role in uncovering the genetic architecture of complex traits.
Understanding Single Nucleotide Polymorphisms
A single nucleotide polymorphism represents a variation at a single position in a DNA sequence among individuals. If more than 1% of a population carries a specific base difference at a locus—such as a cytosine substituted for a thymine—the variation is categorized as a SNP. Millions of SNPs are distributed throughout the human genome, occurring approximately once in every 1,000 base pairs.
Because of their abundance, stability across generations, and ease of high-throughput measurement using modern microarrays and next-generation sequencing technologies, SNPs are ideal markers for large-scale genetic mapping.
The Principles of Genome-Wide Association Studies
Genome-wide association studies (GWAS) are designed to scan complete sets of DNA across large cohorts of individuals to find genetic variations associated with a particular disease or measurable trait. GWAS typically compare two groups:
- Cases: Individuals affected by a particular condition or trait.
- Controls: Unaffected individuals matched by ancestry and demographic factors.
By assaying hundreds of thousands to millions of SNPs across the entire genome in both cohorts, investigators evaluate whether any allele occurs at a significantly higher frequency in individuals exhibiting the trait than in controls.
Mechanism: Linkage Disequilibrium and Proxy Markers
A common misconception is that a SNP identified in a GWAS must directly cause the biological trait or disease. In practice, most identified SNPs do not reside within coding regions and do not directly alter protein structures. Instead, they act primarily as biological markers due to a phenomenon known as linkage disequilibrium (LD).
Linkage disequilibrium describes the non-random association of alleles at different loci on a chromosome. Because segments of chromosomes are inherited together in blocks across generations without being separated by meiotic recombination, a measurable SNP can serve as a proxy for a nearby, unmeasured causal variant.
When a statistically significant association is detected for a given marker SNP, it indicates that the true causal locus is physically close to that marker on the chromosome. Researchers can then fine-map the surrounding LD block to localize the actual functional variant.
Statistical Evaluation and Significance
GWAS rely on rigorous statistical testing to identify associations between individual SNPs and phenotype distributions. For a binary trait, logistic regression is commonly used, while linear regression is applied to quantitative traits.
Because a single study may test up to millions of distinct SNPs simultaneously, correction for multiple hypothesis testing is crucial to minimize false positive results. The standard genome-wide significance threshold is derived using the Bonferroni correction:
\[p < 5 \times 10^{-8}\]
This threshold assumes approximately \(1 \times 10^6\) independent tests across standard linkage disequilibrium blocks in the human genome:
\[\alpha_{\text{adjusted}} = \frac{0.05}{10^6} = 5 \times 10^{-8}\]
Data from these studies are routinely visualized using Manhattan plots, where the genomic position of each SNP is plotted along the horizontal axis, and the negative logarithm of its association p-value, \(-\log_{10}(p)\), is displayed along the vertical axis. Peaks rising above the \(5 \times 10^{-8}\) line indicate genomic regions harboring candidate markers.
Biological Applications and Clinical Translation
Using SNPs as markers across the genome has transformed modern medical genetics and biological research:
- Disease Susceptibility: Identifying risk loci for complex diseases such as type 2 diabetes, coronary artery disease, and psychiatric disorders.
- Polygenic Risk Scores (PRS): Combining the additive effects of multiple associated SNPs across the genome to quantify an individual's genetic susceptibility to specific conditions.
- Pharmacogenomics: Pinpointing SNPs that influence individual variation in drug metabolism, efficacy, and adverse reaction risk.
- Biological Pathway Discovery: Guiding researchers toward previously unsuspected genes, regulatory elements, and cellular pathways implicated in normal development and pathology.